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JONES ET AL., PAGE 1 We show that the times separating the birth of benign, invasive, and metastatic tumor 
cells can be determined by analysis of the mutations they have in common.   When 
combined with prior clinical observations, these analyses suggest the following 
general conclusions about colorectal tumorigenesis:  (i) It takes ~17 years for a large 
benign tumor to evolve into an advanced cancer but less than two years for cells 
within that cancer to acquire the ability to metastasize; (ii) it requires few, if any, 
selective events to transform a highly invasive cancer cell into one with the capacity to 
metastasize; (iii) the process of cell culture ex vivo does not introduce new clonal 
mutations into colorectal tumor cell populations; and (iv) the rates at which point 
mutations develop in advanced cancers are similar to that of normal cells.   These 
results have important implications for understanding human tumor pathogenesis, 
particularly those associated with metastasis.     
 
Colorectal tumorigenesis proceeds through well-defined clinical stages associated with 
characteristic mutations (1, 2) (Fig. 1).  The process is initiated when a single colorectal 
epithelial cell acquires a mutation in a gene inactivating the APC/ -catenin pathway (1).  
Mutations that constitutively activate the KRAS/BRAF pathway are associated with the 
growth of a small adenoma to a clinically significant size (>1 cm in diameter) (3).   
Subsequent waves of clonal expansion driven by mutations in genes controlling the TGF-  
(4, 5), PIK3CA (6), p53 (7) and other pathways are responsible for the transition from a 
benign tumor (adenoma) to a malignant tumor (carcinoma).  The only difference between a 
carcinoma and an adenoma is the ability of the former to invade the tissues underlying the 
colorectal epithelium.   Some tumors eventually acquire the ability to migrate and seed other 
organs (metastasis) (8).   Colorectal tumors can usually be cured by surgical excision at any 
stage prior to this last one, i.e., prior to metastasis to distant sites such as the liver (9).   
 
Understanding the basic features of this evolutionary process has obvious and important 
implications for both scientific and medical research.  But many questions remain.   For 
example, how long does it take for a particular neoplastic cell to acquire the genetic events 
required for each sequential step in this progression?   This question has heretofore been 
impossible to address in individual patients, though relevant information about bulk tumors, 
rather than cells, has been obtained through clinical and radiographic studies (10-12).    We 
here describe an approach that can answer this and related questions.  
 
Large scale sequencing of the vast majority of protein coding genes in human tumors has 
recently become possible and was applied to study the genomes of breast and colorectal 
cancers (13, 14).  In the current study, we investigated whether the mutations discovered in 
the colorectal cancers evaluated in Wood et al. (14) were found in other neoplastic lesions 
from the same patients, an approach we call "comparative lesion sequencing".   We show 
that the sequencing data, when analyzed quantitatively, can be used to determine the time 
intervals required for development of the cells responsible for any two sequential clonal 
expansions.  We were particularly interested in the expansions associated with metastasis.   
This final expansion is the least well understood at the biochemical and physiologic levels, 
even though it is responsible for virtually all deaths from the disease. 
 
Results  
 
JONES ET AL., PAGE 2 Point Mutation Rates and Growth Kinetics of Colorectal Cancers.   Though knowledge of 
the precise mutation rate and tumor growth rates of these lesions are not required to make 
conclusions from comparative lesion sequencing, estimates of these parameters can inform 
their interpretation.  An estimate of the point mutation rate in these tumors can be made on 
the basis of the results reported in (14) wherein 847 non-synonymous mutations were 
detected among 304 million bp sequenced at high quality.  All of these mutations were 
somatic, i.e., not present in the germ-line.   Most of the lesions evaluated in (14) were liver 
metastases and all were mismatch repair proficient.  In order to convert the mutation 
prevalence found in Wood et al. to a mutation rate, it is necessary to know the number of 
divisions that the cancer cell had undergone.  The most reliable way to measure cell division 
time in human tumors is through the administration of DNA precursors such as BrdU to 
patients, followed by evaluation of BrdU incorporation plus DNA content via flow cytometry 
(15) .  This approach yields Tpot, defined as the time between cell divisions in the absence of 
cell death.  Several hundred colorectal cancers have been evaluated by this method, with Tpot 
  measured as ~ 4 days (16-21).  Using this figure for the cell division rate and the mutational 
data reported in (14), the point mutation rate in colorectal cancers is estimated to be 4.6 x 10
-
10 mutations/bp/generation.   This rate is slightly less than that measured in various normal 
cell types (~10 x 10
-10 mutations/bp/generation; (22-25)).  Additional details about this 
estimate are provided in the Supplementary Information.    
 
Comparison of mutations before and after cell culture or xenografting.  The samples 
used in (14) were all derived from colorectal cancer cells that had been passaged for six to 
twelve months in vitro as cell lines or in nude mice as xenografts.  Before initiating the current 
study of other lesions from the same patients, it was important to determine whether the 
mutations identified in the cultured or xenografted cells were actually present in the naturally 
occurring lesions prior to cellular expansion ex vivo.  For this purpose, we analyzed 289 
different mutations found in 18 cell lines or xenografts, each derived from a different patient.   
Five of these had been initiated and passaged in vitro, while the remaining 13 had been 
passaged as xenografts in nude mice.  Two hundred eighty-seven of the 289 mutations 
(99.3%) found in the cell lines or xenografts were also found in the original tumors.  The 
direct Sanger sequencing method we used in the experiments reported herein had a 
sensitivity of ~25%, so that a heterozygous mutation present in less than 50% of the cells 
would not be observed (Fig. 2).  These data therefore indicate that the point mutations found 
in colorectal cancer cell lines or xenografts only rarely arise during in vitro or in vivo 
experimental growth of cells after the tumors are excised from patients.   
 
Comparison of Metastases with Primary Colorectal Cancers.    Paired samples of 
primary colorectal cancers and metastatic lesions from ten patients were available for this 
study.  Of the index lesions (Table 1), seven had been excised from the liver and three from 
mesenteric lymph nodes.  We were able to evaluate an average of 28 mutations per lesion in 
the patients evaluated in the Discovery Screen of (14).  The remaining index lesions had 
been studied only in the Validation Screen, so only ~ 5 mutations could be studied in these 
cases.  In all, 233 somatic mutations identified in the index metastases were evaluated in the 
ten cases.  Of these, only 7 (3.0%, CI 1.5 to 5.7%) were not found in the colorectal cancers 
from which the metastases arose (SI Table 2).   
 
Comparisons of Different Metastatic Lesions.  In 11 of the 13 patients, we were able to 
examine at least one metastatic lesion different from the index lesion of the same patient.  Of 
a total of 261 mutations evaluated, 255 (97.7%) were found in the 29 additional metastases 
JONES ET AL., PAGE 3 studied (Table 1).  This was the expected result, as the great majority of the mutations 
present in metastases were also present in the precursor advanced colorectal carcinoma, as 
noted above.   What was more informative was the study of patients in whom mutations were 
identified in the metastasis but not in the precursor advanced carcinoma (henceforth denoted 
"metastasis-specific mutations").  Though there were only seven of these mutations identified, 
five of them were particularly informative as they could be assessed in other metastatic 
lesions from the same patients.  In patient 5, both of the metastasis-specific mutations 
originally identified in the index liver metastasis were also identified in a mesenteric lymph 
node metastasis.   In patient 7, three liver metastasis-specific mutations identified in the index 
metastasis were identified in a second, independent liver metastasis concurrently excised 
from the patient.  
 
Comparison of Advanced Colorectal Carcinomas with Large Adenomas.  It is believed 
that colorectal carcinomas arise in pre-existing, benign adenomas through the acquisition of 
additional genetic alterations (Fig. 1).  In most cases, the adenomatous tissue is destroyed 
during carcinoma growth.  However, in two of the cases studied here, large residual 
adenomas at the edge of the carcinomas were still present (Fig. 3).  Paraffin-embedded 
sections of these lesions were carefully microdissected to separate adenomatous from 
carcinomatous elements and evaluated for 33 mutations known to be present in the 
carcinoma.  Ten of the 33 mutations (30%) were not found in the adenomatous components.  
The differences between the fraction of mutations found in metastases but not their precursor 
advanced carcinomas and the fraction of mutations found in the advanced carcinomas but 
not in their large precursor adenomas were statistically significant (P<.001, two-group 
binomial test for equality of proportion). 
 O f   t h e   t e n   m u t a t i o n s   i d e n t i f i e d   i n   a d v a n c ed carcinomas but not large adenomas, seven 
were in candidate cancer genes (CAN-genes) as defined in Wood et al. (14).  This proportion 
is significantly different than the proportion of metastasis-specific mutations (12.5%) that were 
in CAN-genes (P<.001, two-group binomial test)) or the proportion of mutations that were in 
CAN-genes among all genes with mutations (16%, p < 0.01, two-group binomial test).  Two of 
the ten mutations identified in carcinomas but not in their precursor adenomas were in TP53, 
consistent with prior data on the timing of TP53 mutations (26) .   
 
Quantification of the Level of Mutations in DNA.  The absence of a somatic mutation in a 
given DNA sample, as assessed by Sanger sequencing, simply means that the mutation was 
not present in >25% of the analyzed DNA template molecules (i.e., >50% of the cells in the 
case of heterozygous mutations).  Mutations present in a smaller fraction can generally not 
be distinguished from the background in sequencing chromatograms.  To determine whether 
the mutations were present in a smaller but still sizable fraction of the tumor cell population, 
we evaluated a subset of the DNA samples via BEAMing (beads, emulsions, amplifications, 
magnetics) assay (see SI Methods) (27, 28).  We performed 20 BEAMing assays in 7 
patients, focusing on those mutations that appeared to be present in late stage lesions but 
not in an earlier stage lesion of the same patient (e.g., present in metastasis but not in the 
advanced colorectal carcinoma).  In 19 of these assays, no mutations were observed 
(examples in Fig. 4).   As the sensitivity of the BEAMing assays was ~0.01%, we conclude 
that less than 1 in 2500 cells in the precursor lesion contained any of these 19 mutations, 
thus suggesting that at least one major clonal expansion occurred between the two stages 
analyzed in each case. 
 
 
JONES ET AL., PAGE 4 Colorectal Cancer Evolution: Mathematical Assessment.  The data in Table 1 can be 
used to determine the relative timing of the birth of the founder cells (Fcells) that gave rise to 
the various tumor cell populations described above (Fig. 5).   The basis for this analysis is 
that all somatic mutations present in clonal fashion in an adenoma (i.e., present in all cells of 
the tumor) must have been present in its cell of origin (its founder cell).  These mutations 
accumulated during the life span of this founder cell and include those that occurred during 
the turnover of normal stem cells prior to the onset of tumorigenesis.   As tumors progress, 
they accumulate additional mutations which become fixed in the founder cells of subsequent 
neoplastic states.  The founder cell of the advanced carcinoma, for example, will harbor all 
the mutations present in the precursor adenoma plus additional mutations that occurred in 
the interim.  The length of this interim period can be estimated by measuring the number of 
additional mutations in the progressed lesion.      
   T h e   f o u n d e r   c e l l s   o f   i n t e r e s t   a r e   ( i )   t h e   o n e   ( F c e l l Met) that gave rise to the final clonal 
expansion resulting in the index metastasis; (ii) the last common ancestor (FcellACa) of the 
advanced carcinoma and FcellMet ; and (iii) the last common ancestor (FcellLAd) of the large 
adenoma and FcellACa.  The birth date of a founder cell is defined as the age of the patient 
when the founder cell underwent its first division.  As shown in the SI Text, the interval 
( TACa,Met) between the birth date of founder cells FcellMet and FcellACa is  
   TACa,Met =  FACa,Met ·TMet   [1] 
where FACa,Met is the fraction of the mutations in the metastasis that were not  found in the 
advanced carcinoma (i.e., 1 – [number of mutations in advanced carcinoma/number of 
mutations in metastasis]).   Similarly, the interval ( TLAd,ACa) between the birth dates TLAd and 
TACa of  founder cells FcellACa and FcellLad, respectively, is   
 (  TLAd,ACa) =  FLAd,ACa· TACa   [2] 
where FLAd,ACa is the fraction of mutations in the advanced carcinoma that were not found in 
the large adenoma.  Similar equations can be applied to any two lesions that represent the 
clonal expansions of two founder cells as long as one of the two founder cells is a direct 
descendent of the other.    
 N o t e   t h a t   t h e s e   e q u a t i o n s   a r e   e n t i r e l y   independent of the actual mutation rates and 
cell division times (Tpot), which likely vary among different patients and cancers.  Additionally, 
they are independent of whether the observed mutations are "drivers" or "passengers", i.e., 
whether the mutations causally contribute to tumor progression.  They only require that the 
mutation rate and cell division times, whatever they are, are constant throughout each 
patient's life.  As described in the SI, this requirement is, in general, expected to be met. 
Mutations thereby act as a clock, providing information similar to that obtained through the 
use of sequence divergence to assess the relatedness of organisms or cells during evolution 
or development (29, 30).    
 
Application to individual patients.  One of the major results of the current study is that 
FLAd,ACa is much greater than FACa,Met, meaning that it takes much longer for a large adenoma 
to evolve into an advanced carcinoma than for such a carcinoma to metastasize.  
Assumptions that limit the accuracy of the times determined through these equations are 
given in the SI Text.  Their implementation can best be illustrated through their application to 
five patients in the current study in whom a minimum of 25 mutations could be evaluated 
(Table 1).  
  Patient 1 was 73 years old when she developed an advanced carcinoma of the 
ascending colon that was 4 cm in diameter and of stage T3N1M0 (T3 refers to the stage of 
the carcinoma, which in this case had grown completely through the muscularis propria; N1 
JONES ET AL., PAGE 5 indicates that cancer was found in at least one but less than four lymph nodes; M0 indicates 
that no distant metastases were evident at the time of surgery).  Fifteen months later, a liver 
metastasis of 5 cm in diameter was found to have developed.  All 47 mutations found in the 
metastasis were also found in the advanced carcinoma in the colon (FACa,Met = 0.0).   
Application of [1] indicated that the metastasis originated from a cell (FcellMet) whose birth 
occurred very soon after the birth of the cell (FcellACa)that founded the advanced carcinoma 
(CI 0 to 3.3 years).  
  Patient 3 was 83 years old when she developed an advanced carcinoma of the 
ascending colon that was 9 cm in diameter and of stage T4N2M1 (N2 indicates that cancers 
cells were found in more than 3 mesenteric lymph nodes).  A residual adenoma that 
surrounded the carcinoma was identified at the time of surgery.  A small (< 1 cm diameter) 
mesenteric lymph node metastasis was found to contain 25 mutations that were 
subsequently evaluated in other lesions of this patient.  Of these, 24 were found in the 
colorectal carcinoma (FACa,Met = 0.04).  Application of [1] indicated that the advanced 
carcinoma founder cell was born 3.2 years (CI 0.4 to 7.1 years) before the lymph node 
metastasis founder cell was born.  In contrast, evaluation of the same mutations in the large 
adenoma from which the carcinoma developed revealed an FLAd,ACa of 0.23.  Application of [2] 
indicated that the large adenoma founder cell was born 17 years (CI 7.7 to 30.6 years) before 
the advanced carcinoma founder cell.  In the ~17 years between the birth of FcellLad and 
FcellACa, the tumor underwent waves of clonal expansion driven by mutations in TP53 and the 
other genes (SI Table 2) presumably required for invasion and further growth of this tumor.  
Once it acquired these capabilities, a cell (FcellMet) capable of lymph node metastasis 
appeared within a relatively short period of time.    
  Patient 5 was 72 years old when he developed an advanced carcinoma of the sigmoid 
colon that was 1.5 cm in diameter and of stage T3N2M1, accompanied by an 8.9 cm liver 
metastasis.   Comparative lesion sequencing indicated that the metastasis founder cell 
FcellMet was born 2.8 years (CI 0.6 to 5.0 years) after the birth of the advanced carcinoma 
founder cell FcellACa.  A large (1.3 cm) mesenteric lymph node metastasis and two smaller 
mesenteric lymph node metastases was also evaluated from this patient.  The larger lymph 
node contained the same 50 mutations identified in the liver metastasis, including the two 
mutations not found in the primary colorectal carcinoma; the two smaller lymph nodes did not 
contain these two mutations.  Thus the 1.3 mesenteric lymph node metastasis and liver 
metastasis founder cells may have both been derived from a small population of cells within 
the carcinoma that had acquired metastatic capability.  Alternatively, the liver metastasis 
could have originated from the large mesenteric lymph node metastasis.  In this case, 
comparative lesion sequencing indicates that the liver metastasis founder cell must have 
been born soon after (0 years, CI 0.0 to 2.0 years) the birth of the of lymph node metastasis 
founder cell.    
  Patient 7 was 55 years old when she developed an advanced carcinoma of the 
ascending colon that was 3.5 cm in diameter and stage T3N1M0.   Twenty months later, two 
metastases of 3.5 and 4 cm diameter were found in the liver.   Comparative lesion 
sequencing of the 4 cm liver metastasis and the colorectal cancer indicated the metastasis 
founder cell was born 6.6 years after the carcinoma founder cell (CI 1.8 to 8.6 years).   Two 
mesenteric lymph node metastases removed at the time of the initial surgery and the 3.5 cm 
liver metastasis noted above were also evaluated.   Three metastasis-specific mutations were 
identified in both liver metastases but not in either nodal metastasis.   
  Patient 13 was 55 years old when he developed an advanced carcinoma of the 
ascending colon that was 2.5 cm in diameter and stage T3N1M1.   A 7 cm metastasis in the 
right lobe of the liver and a metastasis in a mesenteric lymph node were removed at the time 
JONES ET AL., PAGE 6 of surgery.  Twenty-nine months following this resection, a new liver metastasis of 3.1 cm 
diameter was detected in the left lobe and completely excised.  One year later, another 
metastasis in the liver, of diameter 3.5 cm, was identified.  The metastases that were 
identified 29 months and 41 months after the initial diagnosis both had 19 mutations that 
were not found in the advanced carcinoma or metastatic lesions excised at the initial surgery, 
with FACa,Met = 0.28.   In contrast, all of the mutations identified in the metastatic lesions 
removed at the initial surgery were also present in the advanced carcinoma removed 
concurrently.   We interpret this result in the following way.  Chemotherapy consisting of 
irinotecan, leucovorin, and 5-FU administered in the nine months following the initial surgery 
pruned most of the micrometastastic cells remaining in the liver.  One of these cells was 
resistant to the chemotherapy and became the founder cell of the new metastasis and its 
later recurrence.  The chemotherapy had induced many new mutations in this cell, consistent 
with the known mutagenicity of irinotecan and perhaps exacerbated by the 5-FU (31).   
Equation [1] cannot be used to estimate the relative birth date of this cell as comparative 
lesion sequencing requires that the mutation rate be constant throughout the tumorigenic 
process (see SI).  It is notable that this patient was the only one of the patients analyzed in 
depth in our study who had been treated with irinotecan prior to the development of a new 
metastatic lesion.     
 
Discussion 
 
A Temporally-defined Model of Colorectal Cancer.   The data and approach used in the 
current study can be used to temporally model some of the key genetic events in colorectal 
tumorigenesis.  As illustrated in Fig. 5, comparative lesion sequencing suggests that the 
average time interval between the birth of a large adenoma founder cell and the births of an 
advanced carcinoma founder cell is 17 years (CI 10.8 to 26.3 years).   However, the average 
interval between the birth of the advanced carcinoma founder cell and the liver metastasis 
founder cell is only 1.8 years (CI 0.9 to 3.1 years).    
  Information about the birth times of the founder cells giving rise to various neoplastic 
stages has not heretofore been available.  However, our estimates of these values are 
consistent with clinical and radiological observations on bulk tumors.   For example, the time 
between the appearance of small adenomas and the diagnosis of a carcinoma has been 
estimated at 20 to 25 years from studies of patients with familial adenomatous polyposis (11).   
Similarly, serial studies of sporadic colorectal tumor patients have indicated that the transition 
from large adenoma to carcinoma takes ~15 years (11).   Our estimates are also consistent 
with the long doubling times of tumors determined by serial radiologic studies or serial 
measurements of the CEA serum biomarker (10, 12, 32, 33).   Such studies have indicated 
mean doubling times that are generally 2 to 4 months in metastases and much longer in 
adenomas and carcinomas.    
 
Biological Implications.    Our findings suggest that virtually all of the mutations necessary 
for metastasis are already present in all of the cells of the antecedent carcinoma.   These 
data are compatible with two distinct models.  In Model A, none of the carcinoma cells can 
give rise to a metastasis, but they are close to being able to do so; one or a few more genetic 
alterations are required.  In Model B, all of the carcinoma cells can give rise to metastasis; no 
more genetic alterations are required.   Data derived from the current study, involving 
comparisons of different metastatic lesions from the same patients, are compatible with either 
model.   
JONES ET AL., PAGE 7   Model A: If every cell in the cancer cell population were capable of giving rise to a 
metastasis, it is extremely unlikely that any two independent metastases would harbor an 
identical mutation not found in the carcinoma.  However, as described in the Results, we 
identified five metastasis-specific mutations that were each present in more than one 
metastasis from the same patient (patients 5 and 7).   If the founder cells of one of these two 
metastases were not a direct descendent of the other, these data would support the idea that 
a small population of cells within the carcinoma had acquired additional alterations that 
endowed them with the capacity to metastasize.   Such alterations could be the point 
mutations actually identified as metastasis-specific (SI Table 2) or any other heritable event 
(whole chromosome gains or losses, chromosome translocations or amplifications, or certain 
epigenetic changes (34).    
 M o d e l   B :    General support for this model comes from the fact that there so few 
additional alterations identified in the metastases compared to the advanced carcinomas.  
The finding that mutations not found in the carcinoma were identified in two anatomically 
distinct metastases could be explained if the founder cells of the two metastases had both 
come through a bottleneck after they migrated from the primary colorectal carcinoma.  In 
Patient 5, this could have occurred if the liver metastasis had developed from a cell within the 
mesenteric lymph node metastasis that contained the same mutations.  In Patient 7, this 
could have occurred if both liver metastases' founder cell had developed in a lymph node 
metastasis that was not detected or excised.     
 T h e   r e a s o n   t h a t   p r o g r e s s i on of the large adenoma to advanced carcinoma takes so 
much longer than the progression of the latter to metastasis is presumably because many 
more mutations and clonal expansions are required (some of which are indicated in Fig. 5).   
Moreover, some of the genes responsible for the adenoma to carcinoma progression have 
been identified (SI Table 2 and Fig. 5).  One reasonable interpretation of the data is that the 
capacity to invade through layers of the bowel wall without dying, thereby becoming an 
advanced colorectal cancer, is the most challenging step in the process that eventually leads 
to metastasis.  Once that step occurs, few additional steps are required for metastasis to take 
off.   The advent of large-scale cancer genome sequencing provides uniquely valuable 
biomarkers to study tumor evolution.  The study of additional mutations and lesions using the 
approach described in this work could definitively answer a variety of long-standing questions 
about the basic nature of the metastatic process in humans (35-39). 
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Fig. 1.   Major genetic alterations associated with colorectal tumorigenesis.  See SI Text for 
further explanation. 
 
Fig. 2.  Representative examples of sequencing chromatograms of DNA from a xenograft,  
from the metastatic lesion from which the xenograft was derived, and from the patient's 
normal cells.  Note that the ratio of the mutant to wild-type allele in the xenograft is higher 
than that in the metastatic lesion because the latter represented a mixture of neoplastic and 
non-neoplastic cells (stroma, white blood cells, etc.).  The arrow points to the mutated base. 
 
Fig. 3.   Histopathology of representative lesions.   (A)  Primary invasive moderately 
differentiated adenocarcinoma (black circle) with adjacent non-neoplastic colonic mucosa 
(red circle) from patient 2.  (B) Metastatic adenocarcinoma (black circle) to liver (red circle) 
derived from primary colon adenocarcinoma of patient 2.  (C)  Primary invasive moderately 
differentiated adenocarcinoma (black circle) arising in a tubular adenoma (red circle) from 
patient 10.  All sections were stained with H&E and the tissues within each circle were 
separately microdissected.   
 
Fig. 4.  Representative examples of BEAMing assays from the indicated patients and lesions.  
In patient 13, the mutation shown represents one which was present in a new metastasis that 
occurred 29 months following chemotherapy (see text).  The red dots correspond to beads 
attached to mutant DNA fragments (labeled with phycoerythrin [PE]), the blue dots 
correspond to beads attached to wt DNA fragments (labeled with fluorescein [FITC]) and the 
black dots correspond to beads attached to both wt and mutant DNA fragments. 
 
Fig. 5.  Evolution of a lethal cancer.   Each cell-filled cone represents one or more clonal 
expansions (see SI Text for details).   The times required for the evolution of the large 
adenoma founder cell to an advanced carcinoma founder cell ( LAd,ACa), and evolution of the 
advanced carcinoma founder cell to metastatic founder cell (  ACa,Met) were determined by 
comparative lesion sequencing.  Other intervals, such as the time (Texp) required for the 
expansion of the metastasis founder cell FCellMet to the size detected in our patients, were 
estimated as described in SI Text.  The model posits that there are at least two clonal 
expansions, denoted by question marks, that are not associated with any known genetic 
alterations.  
 
 
 
JONES ET AL., PAGE 12 Table 1.   Summary of patient information
Patient #
Wood et 
al. ID#
Age at 
Diagnosis 
Sex
Location of 
colorectal 
tumor
TNM 
Stage*
Site of 
index 
lesion
# mutations in 
colorectal 
adenoma / # in 
carcinoma**
# mutations in 
colorecal 
carcinoma / # in 
index 
metastasis**
# Other 
metastases
 # mutations 
in other 
metastases/ # 
index 
metatasis**
1 Mx27 73 F Ascending T3N1M0  liver NA 47/47 3 24/24
2 Mx29 50 M Descending T4N1M1  liver NA 7/7 3 17/17
3 Mx34 83 F Cecum T4N2M1  lymph 
node
17/22 24/25 4 31/31
4 Mx40  75 F Cecum T4N1M0  lymph 
node
NA 5/5 3 9/9
5 Mx43 72 M Sigmoid T3N2M1  liver NA 48/50 5 98/98
6 Co92 47 F Cecum T3N2M0  liver NA 8/8 0 NA
7 Mx32 55 F Ascending T3N1M0  liver NA 28/32 3 39/45
8 Co84 41 M Cecum T4N2M1  lymph 
node
NA 4/4 0 NA
9 Mx38 65 M Rectum yT3N1M0 liver NA 6/6 3 17/17
10 Co82 80 F Cecum T3N1M0  colon 6/11 NA 1 5/5
11 Mx26 46 F Cecum T2N2M1 liver NA NA 1 3/3
12 Co108 76 F Ascending T4N0M1  liver NA NA 1 6/6
13 Mx41 55 M Ascending T3N1M1 liver NA 49/49*** 2 6/6***
Average 
or Total
63 23/33 226/233 29 255/261
* T2 - carcinoma invaded muscularis propria; T3 - carcinoma invaded  through muscularis propria into submucosa; T4 - carcinoma invaded through wall of colon 
into nearby tissues or organs; N0 - no lymph node involvement; N1 - cancer cells found in 1 to 3 nearby lymph nodes; N2 - cancer found in more than 3 nearby 
lymph nodes: M0 - No distant metasases identified; M1 - Distant metastasis identified; a "y" prior to the TNM stage means that the patient was treated with 
chemoradiotherapy prior to surgery to reduce the size of the lesion.
** The numbers refer to the mutations that could be successfully sequenced.  Not all mutations in an index metastatic lesion could be sequenced in other lesions of 
the same patient because of limitations in available material.
*** There were 49 mutations detected in the liver and two lymph node metastases that were removed at the time of surgery.  A new metastasis developed 29 
months later, following chemotherapy.  This late metastasis contained 19 new mutations that were not present in the original metastases or carcinoma and are not 
included in this Table (see text).
NA, not applicable because indicated comparison could not be performed.Table 2.   Genes specifically mutated in metastases or carcinomas.
A.  Mutations identified in metastasis but not precursor colorectal carcinoma
Gene Patient #
PLCG2 3
CORO1B 5
KCNC4 5
CRB13 7
ENPP2 7
GPR50 7
P2RY14 7
B.  Mutations identified in colorectal carcinoma but not precursor adenoma
Gene Patient #
CACNA2D3 3
HUWE1 3
SFRS6 3
TP53 3
RYR2 3
C1QR1 10
AGC1 10
NUP210 10
TP53 10
TTN 10Methods 
Samples and DNA purification.  DNA samples from tumor samples or their derived 
xenografts or cell lines were obtained and purified as described previously (1).  DNA 
from frozen tissues was purified by a slight modification of a previously described 
method (2).  In brief, frozen tissue was dissolved in guanidine.  After overnight 
ultracentrifugation through cesium chloride, the RNA was pelleted by centrifugation, the 
guanidine layer was removed and ~4 ml of the cesium chloride layer containing the 
genomic DNA was carefully collected.  The DNA was precipitated with ethanol, then 
dissolved in water and treated overnight with proteinase K.  The proteinase K-digested 
DNA was further purified by phenol/chloroform extraction and ethanol precipitation.    
Enriched populations of neoplastic cells were obtained from paraffin embedded sections 
by microdissection.  DNA was purified from these cells using the QIAamp® DNA Micro 
Kit from Qiagen (Valencia, CA) as directed by the manufacturer.   All samples were 
obtained in accordance with the Health Insurance Portability and Accountability Act 
(HIPPA). 
 
DNA Sequencing.  PCR amplification and sequencing were carried out as described 
previously (1).  In brief, 289 exons in which a mutation had been identified previously in 
an index lesion studied in (1) or (3) were PCR-amplified in all other available DNA 
samples from the patient.  DNA samples from xenografts, cell lines and frozen tissues 
were amplified using the primers described previously (3).  New amplicons of smaller 
size were designed for the DNA purified from paraffin-embedded samples.   PCR 
products >250 bp in length were purified using AMPure (Agencourt Biosciences, 
Beverly, MA) and sequenced with M13 forward primer (5’-GTAAAACGACGGCCAGT-
3’) and Big Dye Terminator Kit v.3.1. (Applied Biosystems, Foster City, CA).  Smaller 
amplicons  from paraffin-embedded tissues were purified using a DirectPrep 96 
Miniprep Kit (Qiagen)  and sequenced using Big Dye Terminator kit v.1.1.  The 
CleanSeq kit (Agencourt Biosciences, Beverly, MA) was used to remove excess dye 
terminators from the reaction before visualization by capillary electrophoresis on an ABI 
PRISM 3730xl instruments (Applied Biosystems).  Sequence traces were aligned to the 
genomic reference sequence and analyzed using Mutation Surveyor software 
(SoftGenetics, State College, PA).   
 
Quantification Of Mutation Frequencies In Specific Samples.    When sequencing 
chromatograms were difficult to interpret in the DNA purified from tumor samples, we re-
evaluated the mutation in question either by cloning the PCR product and sequencing 
individual clones or by performing a BEAMing assay.  Cloning of PCR products was 
carried out as previously described (4).  For BEAMing, PCR is performed in water-in-oil 
microemulsions containing beads, specific primers, and Taq polymerase (5).  In 
aqueous compartments containing a template molecule and a bead, the amplification 
products become tightly bound to the bead.   At the end of the process, these beads 
each contain hundreds of thousands of identical copies of the template molecule.  The 
beads can be analyzed via flow cytometry following hybridization to labeled probes 
containing mutant or wt sequences.   
BEAMing assays in the current study were performed essentially as described 
previously (6).  The target region was amplified using gene-specific primers with 5’ tags 
JONES ET AL., SUPPLEMENTAL INFORMATION, PAGE 1 (F tag: 5’-TCCCGCGAAATTAATACGAC-3’; R tag: 5’-GCTGGAGCTCTGCAGCTA-3’) 
and Phusion high fidelity DNA polymerase (New England Biolabs, Beverley, MA).  The 
resulting products were quantified with the PicoGreen dsDNA assay kit (Invitrogen, 
Carlesbad, CA).  Fifty to 150 pmoles PCR product were used as a templates for 
emulsion PCR using  
F tag-labelled streptavadin-coated beads and F tag and R tag as forward and reverse 
primers, respectively.  The emulsions were broken and beads purified using a magnet.  
The beads were hybridized to a fluorescein-labeled probe specific for the wt sequence 
and a biotin-labeled probe specific for the mutant sequence.  After incubation with 
phycoerythrin-labeled streptavidin, mutant and wild type alleles were distinguished by 
flow cytometry   In addition to using BEAMing to help interpret the result of questionable 
sequencing chromatograms, we used this technique to determine the maximum number 
of cells in a tumor cell population that harbored a specific mutation (see main text). 
   
Supplementary Text  
 
Mathematical Analysis of Comparative Lesion Sequencing.  The number of somatic 
mutations (Ni) that have accumulated in celli is linearly related to the mutation rate ( ) 
by the following equation: 
        Ni =  ·Q·Gi,              [3] 
where Q is the number of bp in the genome and Gi is the number of generations that the 
cell has undergone.  The mutation rate   is measured as mutations/bp/generation and is 
assumed to be constant over time. 
If two cells (Cell1 and Cell2) have always had the same mutation rate, then the ratio of 
their accumulated mutations is thus given by 
        N1/N2 = G1/G2 .            [4] 
In the cases considered in this study, founder cell FCell2 is a progeny of founder cell 
FCell1 and both founder cells were derived from a precursor cell that contained no 
somatic mutations.    Hence, 
 N 2 = N1 + F1,2· N2,            [5] 
where F1,2 is defined as the fraction of the total somatic mutations present in Fcell2 that 
are not present in Fcell1 (i.e., F1,2 = 1 - N1/N2).      Note that because Fcell2 is a progeny 
of Fcell1, there can be no mutations in Fcell1 that are not also in Fcell2, so N2 > N1 and 
F1,2   0.                         
 T i is defined as the time during which Ni somatic mutations have accumulated in 
celli. Ti  is then the product of Gi and the cell cycle time, Tpot, i.e., 
 T i  =  Gi· (Tpot)i      [ 6 ]  
If the average Tpot during mutation accumulation in both cells is identical, then [4] can be 
reduced to   
 N 1/N2 = T1/T2.            [7] 
Combining [5] and [7] gives 
   T1,2 = T2 – T1 = T2· F1,2          [8]  
Note that this equation is independent of the actual mutation rate   or the actual cell 
cycling time Tpot of the tumors that are analyzed.  The average  T values reported in the 
text are therefore independent of variations in these two parameters among different 
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the number of somatic mutations identified, as described in the next section. 
 
Confidence Intervals For Estimates of  T1,2.  Consider the case when N1 mutations 
are observed at T1 and N2 - N1 additional mutations are observed at T2. Here T2 is 
known (say the age at diagnosis) while T1 is unknown. Mutations are assumed to occur 
at a constant rate   and events are assumed to be Poisson distributed. Using prior 
distributions Beta (a,b) on the unknown T1/ T2, and Gamma (0,0) on  , we can derive 
the a posteriori distribution.  The Beta and Gamma prior distributions were chosen 
because of their computational convenience and the interpretability of the input   
values as events in hypothetical previous experiments (7).  Whenever feasible, input 
values were chosen to represent vague a priori knowledge.  The two unknowns turn out 
to be statistically independent:   is distributed as Gamma (N2,T2) while the ratio T1/ T2 is 
distributed as Beta (N1+a, N2-N1+b). Thus T2·(N2+a)/(N1+a+b) is the a posteriori mean of 
the unknown T1 given T2, and the Beta distribution can be used to construct highest 
posterior density regions (denoted as 90% CI's in the text). These results apply at the 
individual patient level. As long at the ratio T1/ T2 is constant across patients, the 
distribution of T1/ T2 remains as above, with N1 and N2 representing the sum of the 
mutations found in all patients.  It can be proven that this applies also to the case in 
which each patient's tumor has a different mutation rate.   Using this method one can 
derive the distribution of a birth date T1 conditional on the next birth date T2.  We applied 
this recursively to determine earlier birthdates such as TLAd, in which case uncertainty 
about TACa is also taken into account. 
 F o r   p o o l e d   a n a l y s e s   a n d   f o r   t h e   t r a n s i t i o n   f r o m   T LAd to TACa we used 
"noninformative" choices a=b=0.  For patient-specific analysis of transitions from TACa to 
TMet this was not possible because in some cases there were no mutations that were 
present in the metastasis but absent in the primary colorectal carcinoma.   We therefore 
used an empirical Bayes approach for TACa to TMet  and estimated  (a+b) as (1/ ) - 1 
where   is the "overdispersion parameter"(8) for a beta-binomial model.  This 
approximation allows for some variation in T1/ T2 across patients.   Also, we took a/(a+b) 
to be the relevant overall proportion across patients.   
 A l l   s t a t i s t i c a l   a n a l y s e s   w e r e   p e r f o r m e d   i n   t h e   s t a t i s t i c a l   p a c k a g e   R .     T h e   ' a o d '  
library was used to estimate the beta-binomial model. 
  
Assumptions and Other Areas of Uncertainty.   
 ( i )     M u t a t i o n   r e v e r s i b i l i t y .   One of the assumptions made in deriving Equation 1 is 
that mutations are irreversible and that all mutations observed in Fcell1 are present in 
Fcell2.    We know of no evidence inconsistent with this assumption.  Moreover, it is 
supported by the fact that nearly every mutation initially discovered in a late lesion (e.g., 
metastasis), then found in the carcinoma of the same patient, was also found in all other 
metastatic lesions from that patient (247 of 248 instances examined).  
  
 ( i i )     M u t a t i o n   c o n s t a n c y .   We assume that the mutation rate during normal 
epithelial stem cell growth and tumorigenesis is constant.   This is not true for tumors 
with mutator phenotypes, such as those with mismatch repair deficiency, as the rate of 
mutations in these tumors increases by 100-fold or more in the tumors once both alleles 
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the current study, or in that of (3) were MMR-deficient.  Moreover, as described in the 
main text, the mutation rate measured in the analyzed tumors was similar to, but slightly 
less, than those measured in normal cells.   Somatic mutation rate measurements in 
normal cells such as fibroblasts or lymphoblasts have yielded highly consistent results.  
For example, mutations in HGPRT or glycophorin A result in dominant phenotypes that 
have been measured in several studies as ~1 x 10
-6 mutations/gene/generation (11-13).   
Given the conventional rule of thumb that there are ~1000 nt in or around these genes 
that can result in the mutant phenotype (14), this is equivalent to ~10 x 10
-10 
mutations/bp/generation.  Estimates of the in vivo mutation rate of human colorectal 
epithelial stem cells can be made from the study of O-acetylated sialoglycoproteins (15, 
16).  Such studies have shown a gradual accumulation of mutations with age.  Based 
on the published correlation of age vs. mutation frequency, we calculate a rate of ~3.2 x 
10
-10 mutations/bp/generation after applying the 1000 nt convention and the Tpot 
described in section (iv) below.  This value is similar to the one we calculated for cancer 
cells (~4.6 x 10
-10 mutations/bp/generation). These results, in aggregate, suggest that 
the rates of mutation of colorectal epithelial cells, whether normal or neoplastic, are very 
similar.  Though this rate may differ between patients, such inter-patient differences are 
immaterial to our analysis:  the assumption made in the current study is that the 
mutation rate does not change over time within any given individual.  The average 
somatic mutation rate in tumors in the main text was calculated according to [3], using N 
of 847 mutations, Q of 340 Mb, and G of 5384 generations (G = average TMet divided by 
Tpot).   
 
  (iii) The nature of clonal mutations.   "Clonal mutations" are defined as those 
which are present in every cell of an analyzed population.   By definition, each of these 
clonal mutations are present in the founder cell of the population.  As the progeny of this 
founder cell increase in number, additional mutations (sub-clonal) accumulate.  But 
such sub-clonal mutations are not relevant to our model. 
 T h e   n o t i o n   o f   c l o n a l i t y   a n d   i t s   r e l a t i o n s h i p   to founder cells can be confusing but is 
essential for understanding the derivations of equations [1] to [8].   For example, the 
adenoma cells we purified could have had clonal mutations that were not present in the 
analyzed carcinoma.   This could occur if founder cell of the carcinoma branched off 
early during the evolution of the adenoma, but then the adenoma evolved further, 
accumulating additional mutations that allowed it to grow larger but not to grow 
invasively (i.e., not allowing it to become a carcinoma).   The initial adenoma cells that 
developed from FCellLad and gave rise to the carcinoma could have been destroyed and 
replaced by subsequent round(s) of clonal expansion that resulted in the adenoma cells 
we analyzed.   Because this progressed adenomatous lesion will have all of the 
mutations present in FcellLad, however, the analysis and calculated  TLAd,ACa are 
unaltered.     
 T h o u g h   n o t   p e r f o r m e d   h e r e ,   o n e   c o u l d   use the same heuristic approach to 
determine the evolutionary time separating the founder cells of two lesions when neither 
founder cell is a direct descendent of the other, i.e., cell populations on different 
branches of a tumor evolutionary tree.    For example, one could analyze a lymph node 
metastasis and a liver metastasis even when the latter did not develop directly from the 
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one would have to perform an unbiased mutational analysis of each lesion in an 
independent manner and could not rely on an evaluation of only those mutations that 
were present in the most advanced lesion (as was done in the current study).    
    
  (iv) Estimates of Tpot.   Tpot is defined as the cell division time that would occur in 
the absence of any cell death.   This parameter was used in two instances in our 
analysis.   First, we used a value of Tpot of 4 days in the estimation of somatic mutation 
rates in cancers as described in (ii) above.   Studies in hundreds of patients have shown 
that the value of Tpot generally ranges from 3 to 5 days (17, 18) (19-21).   Substitution of 
3 or 5 days for 4 days as the Tpot would not substantially alter the conclusion that the 
somatic point mutation rate in cancers is very similar to that observed in normal cells.   
Second, it was assumed that the Tpot of normal and neoplastic colorectal epithelial cells 
is identical throughout life in deriving [7].  This equation is not dependent on the actual 
value of Tpot,  but as with the mutation rate, requires that it be constant throughout the 
lifetime of an individual patient.  Justification for this assumption in neoplastic cells is 
provided by the fact that the measured values of Tpot are similar (3 to 5 days) in patients 
with different stage lesions (17-21).  The Tpot of normal human colorectal epithelial stem 
cells has not been measured.  However, a value of 4 days for the Tpot of such normal 
cells seems reasonable given the studies of O-acetylated sialoglycoproteins noted 
above plus the observation that stem cells in the mouse intestine cycle very frequently 
(periods of one day in small intestine, somewhat longer in large intestine) (22) .   
  
 ( v )     E s t i m a t e s   o f   T 2.   In Equation [8],  T is defined as the product of T2 and F1,2.  
F1,2 is determined experimentally but T2 must be estimated.  T2 is defined as the age of 
the patient when Fcell2 was born.   When Fcell2 is the founder cell of a metastasis,  
  T2 = TMet = Tdx – Texp,      [9]  
where Tdx is the age of the patient when the lesion was detected and Texp is the time 
during which FcellMet underwent the clonal expansion that resulted in the metastasis.   
  Minimum and maximum estimates of Texp can be obtained from previous studies. 
For example, a metastatic lesion of 3.5 cm contains 2.24 x 10
10 cells, assuming 10
9 
cells/cm
3.   Starting from one cell, this expansion represents 34.3 doublings.   If there is 
absolutely no death of cells, so that tumor size is only limited by the cell cycle time Tpot 
(17-20);Rew, 1991 #7303}, then Texp = 34.3 doublings x 4 days/doubling = 0.38 years .  
If on the other hand, the measured tumor doubling time (23-25) is used, then Texp = 34.3 
generations x 60 days/generation  = 5.6 years.   In the current study, we estimated Texp 
for metastases as 2 years based on the expectation that the cells would multiply rapidly 
at the outset of the expansion, when nutrients and angiogenesis are not limiting, but 
would multiply at the rate predicted by the tumor doubling time once they became 
radiologically visible (26) .  Because these doubling times differ so much among 
patients, we made no attempt to estimate their values in individual patients and instead 
used 3 years for all patients.  Note that whichever of these estimates is used, Texp is 
less than 10% of Tdx, as the average age of our patients was 63 years.   From [9], the 
estimate of Texp will not substantially affect TMet and from [8], the estimate of TMet will not 
have a large influence on  T.   
 
JONES ET AL., SUPPLEMENTAL INFORMATION, PAGE 5   (vi) Timelines in Fig. 5.  The time required for the clonal expansion giving rise to 
the metastasis is Texp, as described in section (v) above.   The average TMet  was 
calculated using [9].  The average TACa  was calculated as Tdx - Texp -  TACa,Met.   The 
average TLAd  was calculated using the data in Table 1 and Equation [2].   The time 
required for growth of an initiated cell to a large adenoma was estimated as Y -  TACa,Met 
-    TlAc,ACa.  where Y is the average time thought to be required for development of an 
advanced carcinoma from an adenoma. We estimated Y as 25 years on the basis of 
published studies that evaluated patients with sporadic or familial colorectal neoplasms 
over time (26, 27). 
 
  (vii)  Other features of Figures 1 and 5.  It is assumed that the founder cell of the 
microadenoma was a normal colorectal epithelial stem cell such as that described in 
Barker et al. (22).  Whether this stem cell is located at the bottom (as shown) or tops of 
the crypts is debatable (28).  Modeling studies suggest that chromosomal instability 
(CIN) occurs relatively early in colorectal tumorigenesis ((29)).  Recent data shows that 
CDC4 and several other putative CIN genes affect chromatid cohesion (30).  Because 
CDC4 mutations are known to occur in small adenomas (31), alterations of the 
CDC4/CIN pathway are placed early in the model.  It is known that KRAS/BRAF 
pathway gene mutations occur in large adenomas but rarely in small adenomas.  
Mutations in PIK3CA/PTEN, TP53/BAX, or SMAD4/TGF RII pathway genes are rarely 
observed in large adenomas but are often observed in carcinomas.  These three 
pathways are therefore likely to be involved in the transition from benign lesions (large 
adenomas) to progressive malignancies (early carcinomas).  Though represented as 
discrete steps in the model, these stages represent a continuum.  The relative order of 
PIK3CA/PTEN, TP53/BAX, or SMAD4/TGF RII mutations is conjectural, though it is 
broadly consistent with previous studies (e.g., (32-38)). Though each of the indicated 
pathways are likely altered in the majority of colorectal cancers, every cancer does not 
have an alteration in every pathway; variations among tumors contribute to their biologic 
heterogeneity (1).  The genes listed adjacent to the arrows represent the most 
frequently mutated genes in the pathways; other mutant genes can affect the same 
pathways (39, 40).  Each cone represents one or more clonal expansions, as explained 
in section (iii) above.  It has been estimated that 10 to 20 driver mutations are 
accumulated during the tumorigenic process (41); some of these are likely to be 
responsible for additional clonal expansions within the cones.  We speculate that at 
least one additional mutation is required to evolve an advanced carcinoma (stage T3 or 
T4, defined as having invaded through the muscularis propria; see legend to Table 1) 
from an early carcinoma.  The pathway(s) responsible for the transition from early to 
advanced carcinoma has not yet been identified, though some evidence suggests that 
the SMAD4/TGF RII pathway may play a role (34-38).  As noted in the main text, it is 
not clear whether the process of metastasis requires any additional mutations other 
than those observed in the advanced carcinoma. 
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